This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Innovative and adaptive strategies for new drug development are needed to maximize the potential of cell and gene therapies. CRA’s Lev Gerlovin with co-authors Walter Colasante and Pascale Diesel explain in this Cell and Gene article. Click here to read the article.
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences...
Access to medicine and healthcare services poses persistent challenges, especially in low-income regions with high out-of-pocket expenses. Pharmaceutical...
Kirsten Axelsen moderates the PhRMA-sponsored panel session titled “Progress or Regress…How does CMS’ Maximum Fair Price Negotiation align with...
CRA is a proud sponsor of the MAPS organization. Ayushman Ghosh and Michelle Guo host the roundtable discussion titled “Strategic applications of Machine...
